Newsletter
| Promoter: | USA Market News | Paying Party: | UNKNOWN |
| Stocks covered: | Compensation: | Avg $ Volume for Period: |
| POSC | $25000 | 94159 |
| Max Profit: 37.59 % | Gain at close: 12.06 % | |
| *We think that this promoter is a part of a group of promoters. | ||
Hi Subscriber,
Overview
Positron Corporation (POSC) (the “Company” or “Positron”) is a molecular imaging company that provides unique solutions for the Nuclear Medicinecommunity through the production and distribution of molecular imaging devices and radiopharmaceutical products. Positron’s proprietaryproduct lines and services include; the Attrius®, a dedicated PET imaging system; PosiStar™, a world-class clinical, technical and servicecustomer care plan; PosiRx™, a system that automates the elution, preparation and dispensing processes for radiopharmaceutical agents used inmolecular imaging; and the Tech-Assist™, a PET infusion and shielding system.
Snapshot. (POSC) Closed Friday at .0125
Major developments and milestones achieved by Positron Corporation during 2010 include:
· Launch of the Attrius® – the only FDA approved standalone PET scanner optimized for cardiac imaging;
Launch of the Attrius® – the only FDA approved standalone PET scanner optimized for cardiac imaging;
· Attrius® named “Most Innovative Device of 2010” by Frost & Sullivan;
Attrius® named “Most Innovative Device of 2010” by Frost & Sullivan;
· 15 Attrius® PET systems under sales contracts, 5 systems installed and revenue recognized;
15 Attrius® PET systems under sales contracts, 5 systems installed and revenue recognized;
· Signed co-development agreement with Covidien to develop technology for an innovative distribution model of radiopharmaceuticals
based on a customized Positron device;
Signed co-development agreement with Covidien to develop technology for an innovative distribution model of radiopharmaceuticals
based on a customized Positron device;
· Completed initial development of PosiRx™ formerly named Cardio-Assist™ – Positron’s proprietary automated compounding and unit
dose dispensing device;
Completed initial development of PosiRx™ formerly named Cardio-Assist™ – Positron’s proprietary automated compounding and unit
dose dispensing device;
· Acquired pharmaceutical manufacturing facility for development of radiopharmaceuticals and contract manufacturing;
Acquired pharmaceutical manufacturing facility for development of radiopharmaceuticals and contract manufacturing;
Conclusion:
We think could be a outstanding value at its current price. The stock is trading under $.02 right now, and looks like a aggressive play for our subscribers to make some profits in the near term. It could be the play of the month so far!DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT OR WEBSITE unless you can afford to lose your entire investment .. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. USAMarketNews.com is a wholly owned subsidiary of Raven Consulting Corp. Currently Raven Consulting Corp expects to be compensated $25,000.00 for this POSC Positron Corp advertising and promotion by a third party. All direct third party compensation received will be fully disclosed in any communication regarding a profiled company. This website is a service of Raven Consulting,, Corp, a financial public relations firm that has been compensated by the companies profiled. All direct and third party compensation received has been disclo sed within each individual profile in accordance with section 17(b) of the Securities A c t of 1 9 3 3. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled companies. Raven Consulting Corp, and/or its affiliated will hold, buy, and sell securities in the companies profiled. When compensated in shares, all readers should be aware that is our policy to liquidate all shares immediately. We reserve the right to buy or sell the shares of any the companies mentioned in any materi als we produce at any time. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled companies. The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer t o buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them. Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any of the companies’ profiled based solely on information contained in our report. Individuals should assume that all information contained in the report about profiled companies is not trustworthy unless verified by their own independent research. Full disclaimer can be read at www.usamarketnews.com/disclaimer.html